Semafore Pharmaceuticals
As of the edition of 20 October 2026, Semafore Pharmaceuticals runs 1 drug; it is on route A at 5 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
Where it needs a new molecule
Route A at 5 targets, route B at 0 targets.
| Target | Route |
|---|---|
| PIK3CB Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Route A |
| PIK3CG Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Route A |
| PIK3CD Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Route A |
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Semafore Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 1 trials led